Abstract: A system and method for prefetching one or more embedded objects marked uncacheable using a buffer on a prefetch cache to temporarily store the uncacheable object. The buffer is allocated to a socket that is established between the prefetch cache and a server subsequent to the establishment of an initial connection. A prefetch caching process retrieves one or more embedded objects from the server using the socket based on the preconfigured set of rules. The prefetch caching process determines whether the embedded object is uncacheable, and if so loads the object into the buffer. The prefetch caching process waits a predetermined time period for client request for the object. If the request is received prior to expiration of the time period, the prefetch caching process sends the object to the client. Otherwise, the process “flushes” the buffer, thereby discarding the object, and then closes the socket.

Abstract: A system and method for prefetching one or more embedded objects marked uncacheable using a staging area on a prefetch cache to temporarily store (load) the uncacheable object. The staging area is a buffer allocated to a socket that is established between a prefetch cache and the server subsequent to the establishment of an initial connection. A prefetch caching process retrieves one or more embedded objects from the server using one or more sockets 145 based on the response sent to the client and a preconfigured set of rules. Additionally, the prefetch caching process determines whether the embedded object is uncacheable. The prefetch caching process then loads the object into the buffer associated with the socket. The prefetch caching process waits a predetermined time period for the cache to receive a client request for the object. If the request is received prior to expiration of the time period, the prefetch caching process sends the object over the socket.

Abstract: The present invention is directed to the discovery that (3S,4R)-3,4-dihydro-4-(2,3 -dihydro-2-methyl-3-oxopyridazin-6-yl)oxy-3-hydroxy-6-(3 -hydroxyphenyl)sulphonyl-2,2,3-trimethyl-2H-benzo[b]pyran may be used to promote hair growth and alleviate alopecia.

Abstract: Certain exemplary embodiments provide a healthcare information management system, comprising: an interface processor for automatically electronically acquiring information for use in identifying completion status of a plurality of electronic patient healthcare records of a corresponding plurality of different patients; a data analyzer for analyzing said acquired information to derive data indicating, (a) a first number of electronic patient healthcare records to be updated in response to events occurring during a predetermined time period, and (b) status of a second number of said electronic patient healthcare records as being at least one of, (i) complete and (ii) incomplete; and an output processor for processing said derived data to be suitable for communication.

Abstract: Methods useful for inhibiting the release of interleukin-1 and for alleviating interleukin-1 mediated conditions, such as IL-1-mediated inflammation, comprising administration of an effective amount of a pharmaceutically acceptable antioxidant compound such as disulfiram, tetrakis [3-(2,6-di-tert-butyl-4-hydroxyphenyl)propionyloxy methyl]methane or 2,4-di-isobutyl-6-(N,N-dimethylaminomethyl)-phenol.

Abstract: Methods useful for inhibiting the release of interleukin-1 and for alleviating interleukin-1 mediated conditions, such as IL-1-mediated inflammation, comprising administration of an effective amount of a pharmaceutically acceptable antioxidant compound such as disulfiram, tetrakis [3-(2,6-di-tert-butyl-4-hydroxyphenyl)propionyloxy methyl]methane or 2,4-disobutyl-6-(N,N-dimethylaminomethyl)-phenol.

Abstract: Methods useful for inhibiting the release of Interleukin-1 and for alleviating interleukin-1 mediated conditions, such as IL-1 mediated inflammation, comprising administration of an effective amount of an alkylidenedithiobis(substituted)phenol, preferably, 4,4'-(isopropylidenedithio(bis(2,6-di-tert-butyl) phenol, generically known as probucol.

Abstract: Methods useful for inhibiting the release of interleukin-1 and for alleviating interleukin-1 mediated conditions, such as IL-1-mediated inflammation, comprising administration of an effective amount of a pharmaceutically acceptable antioxidant compound such as disulfiram, tetrakis [3-(2,6-di-tert-butyl-4-hydroxyphenyl)propionyloxy methyl]methane or 2,4-di-isobutyl-6-(N,N-dimethylaminomethyl)-phenol.